| [1] |
Mottet N, Bergh RCN, Briers E, et al. EAU-ESTRO-SIOG guidelines on prostate cancer[M]. Euro Asso Urol, 2018, 1-146.
|
| [2] |
Moldovan PC, Van den Broeck T, Sylvester R，et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European association of urology prostate cancer guidelines panel[J]. Eur Urol, 2017, 72(2):250-266.
|
| [3] |
Fossati N, Willemse PM, Van den Broeck T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review[J]. Eur Urol, 2017, 72(1):84-109.
|
| [4] |
Randazzo M, Muller A, Carlsson S, et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer(ERSPC, Aarau)[J]. BJU Int, 2016, 117(4):576-583.
|
| [5] |
Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk[J]. N Engl J Med, 2012, 366(2):141-149.
|
| [6] |
Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and processed meat,meat cooking methods, heme iron, heterocyclic amines and prostate cancer[J]. Nutr J, 2015, 14:125.
|
| [7] |
Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: A validated alternative to the gleason score[J]. Eur Urol, 2016, 69(3):428-435.
|
| [8] |
Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J]. Eur Urol, 2014, 65(3):534-542.
|
| [9] |
Bryant RJ, Sjoberg DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study[J]. J Natl Cancer Inst, 2015, 107(7), djv095.
|
| [10] |
Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare[J]. J Urol, 2011, 186(5):1830-1844.
|
| [11] |
von Knobloch R, Weber J, Varga Z, Feiber H, et al. Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy:a prospective randomised trial[J]. Eur Urol, 2002, 41(5):508-514.
|
| [12] |
Bratan F, Niaf E, Melodelima C, et at. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study[J]. Eur Radiol. 2013, 23(7):2019-2029.
|
| [13] |
Fütterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature[J]. Eur Urol, 2015, 68(6):1045-1053.
|
| [14] |
Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasoundguided biopsy: a systematic review and meta-analysis[J]. Eur Urol, 2015, 68(3):438-450.
|
| [15] |
Wegelin O, van Melick HHE, Hooft L, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: A systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive egistration. is There a preferred technique?[J] Eur Urol, 2017, 71(4):517-531.
|
| [16] |
Sammon JD, Trinh QD, Sukumar S, et al. Risk factors for biochemical recurrence following radical perineal prostatectomy in a large contemporary series: a detailed assessment of margin extent and location[J]. Urol Oncol, 2013, 31(8):1470-1476.
|
| [17] |
Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6):941-949.
|
| [18] |
Evangelista L, Bertoldo F, Boccardo F, et al. Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons[J]. Eur J Nucl Med Mol Imaging, 2016, 43(8):1546-1562.
|
| [19] |
Roach PJ, Francis R, Emmett L, et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study[J]. J Nucl Med, 2018, 59(1):82-88.
|
| [20] |
Billaxelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer[J]. N Engl J Med, 2014, 370(10):932-942.
|
| [21] |
Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer[J]. N Engl J Med, 2016, 375(15):1415-1424.
|
| [22] |
Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer[J]. J Clin Oncol, 2015, 33(3):272-277.
|
| [23] |
Gandaglia G, Fossati N, Zaffuto E, et al. Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer[J]. Eur Urol, 2017, 72(4):632-640.
|
| [24] |
Novara G, Galfano A, Secco S, et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients[J]. Urol Int, 2009, 82(3):249-255.
|
| [25] |
Passoni NM, Fajkovic H, Xylinas E, et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis[J]. BJU Int, 2014, 114(4):503-510.
|
| [26] |
Haglind E, Carlsson S, Stranne J, et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: A prospective, controlled, nonrandomised trial[J]. Eur Urol, 2015, 68(2):216-225.
|
| [27] |
Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial[J]. Lancet Oncol, 2015, 16(3):274-283.
|
| [28] |
Lee WR, Dignam JJ, Amin MB, et al. Randomized phase iii noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer[J]. J Clin Oncol, 2016, 34(20):2325-2332.
|
| [29] |
Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 HHiP trial[J]. Lancet Oncol, 2016, 13(1):43-54.
|
| [30] |
Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer[J]. J Clin Oncol, 2017, 35(17):1884-1890.
|
| [31] |
Klotz L, O'Callaghan C, Ding K et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT[J]. J Clin Onco, 2015, 33(10):1151-1156.
|
| [32] |
Østergren PB, Kistorp C, Fode M, et al. Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial[J]. J Urol, 2017, 197(6):1441-1447.
|
| [33] |
Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer:effects on bone mineral density and body composition[J]. J Clin Oncol, 2004, 22(13):2546-2553.
|
| [34] |
van der Poel HG, van den Bergh RCN, Briers E, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018[J]. Eur Urol, 2018, 74(1):84-91.
|
| [35] |
Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities[J]. J Urol, 2007, 178(6):2260-2267.
|
| [36] |
Petrelli F, Vavassori I, Cabiddu M, et al. Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis[J]. Urology, 2016, 91:136-142.
|
| [37] |
Raldow AC, Zhang D, Chen MH, et al. Risk group and death from prostate cancer: implications for active surveillance in men with favorable intermediate-risk prostate cancer[J]. JAMA Oncol, 2015, 1(3):334-340.
|
| [38] |
Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients[J]. Eur Urol, 2010, 58(1):1-7.
|
| [39] |
Zwergel U, Suttmann H, Schroeder T, et al. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy[J]. Eur Urol, 2007, 52(4):1058-1065.
|
| [40] |
Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial[J]. Lancet Oncol, 2016, 17(6):747-756.
|
| [41] |
Fossati N, Karnes RJ, Cozzarini C, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy[J]. Eur Urol, 2016, 69(4):728-733.
|
| [42] |
Fizazi, K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol, 2012,13(10):983-992.
|